188 related articles for article (PubMed ID: 27151361)
1. Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma.
Yip KT; Zhong XY; Seibel N; Pütz S; Autzen J; Gasper R; Hofmann E; Scherkenbeck J; Stoll R
Sci Rep; 2016 May; 6():25119. PubMed ID: 27151361
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.
Yip KT; Zhong X; Seibel N; Arnolds O; Schöpel M; Stoll R
Biointerphases; 2017 May; 12(2):02D415. PubMed ID: 28565914
[TBL] [Abstract][Full Text] [Related]
3. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
[TBL] [Abstract][Full Text] [Related]
4. Processing of MIA protein during melanoma cell migration.
Schmidt J; Bosserhoff AK
Int J Cancer; 2009 Oct; 125(7):1587-94. PubMed ID: 19521988
[TBL] [Abstract][Full Text] [Related]
5. Regulation of integrin activity by MIA.
Bauer R; Humphries M; Fässler R; Winklmeier A; Craig SE; Bosserhoff AK
J Biol Chem; 2006 Apr; 281(17):11669-77. PubMed ID: 16517605
[TBL] [Abstract][Full Text] [Related]
6. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
[TBL] [Abstract][Full Text] [Related]
7. NMR-based Drug Development and Improvement Against Malignant Melanoma - Implications for the MIA Protein Family.
Arnolds O; Zhong X; Tuo Yip K; Schöpel M; Kohl B; Pütz S; Abdel-Jalil R; Stoll R
Curr Med Chem; 2017; 24(17):1788-1796. PubMed ID: 28595551
[TBL] [Abstract][Full Text] [Related]
8. MIA--a new target protein for malignant melanoma therapy.
Schmidt J; Riechers A; Bosserhoff AK
Histol Histopathol; 2013 Apr; 28(4):421-6. PubMed ID: 23192727
[TBL] [Abstract][Full Text] [Related]
9. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration.
Winklmeier A; Contreras-Shannon V; Arndt S; Melle C; Bosserhoff AK
Cancer Sci; 2009 Feb; 100(2):261-8. PubMed ID: 19200257
[TBL] [Abstract][Full Text] [Related]
10. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition.
Schmidt J; Riechers A; Stoll R; Amann T; Fink F; Spruss T; Gronwald W; König B; Hellerbrand C; Bosserhoff AK
PLoS One; 2012; 7(5):e37941. PubMed ID: 22666418
[TBL] [Abstract][Full Text] [Related]
11. [MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma].
Bosserhoff AK; Golob M; Buettner R; Landthaler M; Hein R
Hautarzt; 1998 Oct; 49(10):762-9. PubMed ID: 9857251
[TBL] [Abstract][Full Text] [Related]
12. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
Bosserhoff AK
Pigment Cell Res; 2005 Dec; 18(6):411-6. PubMed ID: 16280006
[TBL] [Abstract][Full Text] [Related]
13. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
14. Migration-associated secretion of melanoma inhibitory activity at the cell rear is supported by KCa3.1 potassium channels.
Schmidt J; Friebel K; Schönherr R; Coppolino MG; Bosserhoff AK
Cell Res; 2010 Nov; 20(11):1224-38. PubMed ID: 20733613
[TBL] [Abstract][Full Text] [Related]
15. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo.
Bosserhoff AK; Echtenacher B; Hein R; Buettner R
Melanoma Res; 2001 Aug; 11(4):417-21. PubMed ID: 11479431
[TBL] [Abstract][Full Text] [Related]
16. Detailed analysis of MIA protein by mutagenesis.
Stoll R; Lodermeyer S; Bosserhoff AK
Biol Chem; 2006 Dec; 387(12):1601-6. PubMed ID: 17132106
[TBL] [Abstract][Full Text] [Related]
17. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.
Stoll R; Renner C; Zweckstetter M; Brüggert M; Ambrosius D; Palme S; Engh RA; Golob M; Breibach I; Buettner R; Voelter W; Holak TA; Bosserhoff AK
EMBO J; 2001 Feb; 20(3):340-9. PubMed ID: 11157741
[TBL] [Abstract][Full Text] [Related]
18. Functional role of MIA in melanocytes and early development of melanoma.
Poser I; Tatzel J; Kuphal S; Bosserhoff AK
Oncogene; 2004 Aug; 23(36):6115-24. PubMed ID: 15208686
[TBL] [Abstract][Full Text] [Related]
19. Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma.
Marr DG; Poser I; Shellman YG; Bosserhoff AK; Norris DA
Int J Oncol; 2004 Jul; 25(1):105-11. PubMed ID: 15201995
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of p66shc by melanoma inhibitory activity.
Kasuno K; Naqvi A; Dericco J; Yamamori T; Santhanam L; Mattagajasingh I; Yang S; Meyskens FL; Bosserhoff AK; Irani K
Cell Death Differ; 2007 Aug; 14(8):1414-21. PubMed ID: 17431427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
